undamentalytics Newsletter
Sign in

Pacira Biosciences, Inc. cash flow statement

In fiscal 2025, Pacira Biosciences, Inc.'s operations generated $152m of cash; it spent $15.3m on capital projects, leaving free cash flow of $137m. It returned $148m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−21−25−31−70−4427283318497177126145155189152188
Depreciation and amortisation4446610111314132020299276799157
Stock-based pay10251225333132323440424848515856
Capital spending67618122340251915103846301511158
Free cash flow−26−32−37−88−564−129−134603980115139179137180
Free cash flow after stock pay−27−32−40−93−68−21−46−23−33327−138679212879124
Share buybacks—0———————————0025148148
Shares issued——49630—————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMPH vs PCRXCORT vs PCRXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pacira Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pacira Biosciences, Inc.